# **Mono- and Dinuclear Ruthenium(II) Complexes of 2,6-Di(pyrazol-3-yl)pyridines: Deprotonation, Functionalization, and Supramolecular Association**

#### **Jerzy Zadykowicz and Pierre G. Potvin\***

Department of Chemistry, York University, 4700 Keele Street, Toronto, ON, Canada M3J 1P3

*Recei*V*ed July 15, 1998*

A number of Ru(II) complexes, both homo- and heteroleptic, of variously N-substituted 2,6-di(4,5,6,7 tetrahydroindazol-3-yl)pyridines have been prepared from the free ligands or by N-alkylations of Ru-bound, *N*-Hbearing ligands. Carboxyl-bearing complexes were prepared by hydrolysis of the corresponding esterified complexes. All were characterized by elemental analysis and by their NMR, FAB-MS, and UV-visible spectra, and a selection was additionally submitted to cyclic voltammetry. The fully substituted complexes showed MLCT bands in the 414-424 nm range and  $E_{1/2}^{3+/2+}$  values in the +0.83-0.98 V range. Comparisons with data from related complexes are discussed. A heteroleptic dinuclear species was prepared from a CH2-linked bis(tridentate) and found to consist of the *like* (chiral racemic) diastereomer. It showed a single MLCT band at 416 nm and a single Ru<sup>3+/2+</sup> couple at +0.98 V. In the case of *<sup>N</sup>*-H-bearing complexes, deprotonation caused the appearance of a less energetic MLCT band and multiple CV waves at lower oxidation potentials. There was also evidence of loss of H• at negative potentials. A supramolecular 2:1 salt formed between the deprotonated form of the homoleptic complex of 2,6-di(1-(4-carboxyphenyl)-4,5,6,7-tetrahydroindazol-3-yl)pyridine and methyl viologen dication.

### **Introduction**

 $Ru^{II}$  complexes of bipyridine (bpy) and terpyridine have attracted much attention due to their potential application as photocatalysts.1 This has stimulated work with other ligands composed of combinations of azines and azoles,<sup>2</sup> including the *π*-rich pyrazolylpyridines and bispyrazolylpyridines. In previous work, we have reported the preparation of the  $3'(C')$ , 2-linked 2-(tetrahydroindazol-3-yl)pyridine, H**1**, from commercially available materials by a short route and in good yields.<sup>3</sup> Ru<sup>II</sup> complexes of H**1** and of several of its 1(N)-substituted derivatives have been prepared and studied in detail.<sup>4,5</sup> Compared with bpy in Ru(bpy)<sub>3</sub><sup>2+</sup>, these showed higher d $\pi$  and  $\pi^*$  levels, with  $E<sub>L</sub>$  parameters<sup>6</sup> of 0.21-0.22 V,<sup>4</sup> but the ligand remained flat in crystals.5



We wished to similarly examine complexes of the tridentate analogue of H**1**, the symmetrical 2,6-di(tetrahydroindazol-3-yl)-

- *\** Corresponding author. Tel.: (416) 736-2100, ext. 66140. Fax: (416) 736-5936. E-mail:pgpotvin@yorku.ca.
- (1) Sauvage, J.-P.; Collin, J.-P.; Chambron, J.-C.; Guillerez, S.; Coudret, C.; Balzani, V.; Barigelletti, F.; De Cola, L.; Flamigni, L. *Chem. Re*V*.* **1994**, *94*, 993.
- (2) E. C. Constable, *Ad*V*. Inorg. Chem. Radiochem.* **<sup>1986</sup>**, *<sup>30</sup>*, 69.
- (3) Luo, Y.; Potvin, P. G. *J. Org. Chem.* **1994**, *59*, 1761.
- (4) Luo, Y.; Potvin, P. G.; Tse, Y.-H.; Lever, A. B. P. *Inorg. Chem.* **1996**, *35*, 5445.
- (5) Luo, Y.; Potvin, P. G. *J. Coord. Chem.* **1999**, *46*, 319.
- (6) Lever, A. B. P. *Inorg. Chem.* **1990**, *29*, 1271; **1991**, *30*, 1980. Masui, H.; Lever, A. B. P. *Inorg. Chem.* **1993**, *32*, 2199.

pyridine H2**2**, which is also easily prepared.7,8 Like H**1** but unlike the  $1'(N')$ , 2-linkage isomers, <sup>9,10</sup> H<sub>2</sub>**2** is amenable to modification at the 1(*N*)-H sites. This facility has enabled us to prepare a variety of substituted tridentates $8,11,12$  and a ditopic bis(tridentate)<sup>11</sup> as well as novel pentadentate and macrocyclic<sup>7</sup> ligands. We have also demonstrated how these ligands can bind alkali metal ions, Fe(III),  $Ru(II), ^{7,11,13} Zn(II), ^{11}$  and Co(II).<sup>12,14</sup> The liposolubilities of H**1** and H2**2** and their derivatives and complexes have proven to be synthetically very advantageous.



We now report on the preparation and characterization of  $Ru<sup>H</sup>$  complexes of a number of derivatives of  $H<sub>2</sub>$ , including a dinuclear species, on the novel alkylation of *N*-H-bearing complexes and on supramolecular binding of methyl viologen by a COOH-bearing complex.

<sup>(7)</sup> Dash, R.; Potvin, P. G. *Can. J. Chem.* **1992**, *70*, 2249.

<sup>(8)</sup> van der Valk, P.; Potvin, P. G. *J. Org. Chem.* **1994**, *59*, 1766.

**Scheme 1**



Method A'

 $\frac{1}{2}$  Ru(DMSO)<sub>4</sub>Cl<sub>2</sub> DBU / LiCI  $NH_4PF_6$ L  $[Rul_2](PF_6)_2$  $E$ <sub>1</sub>A  $(CH_2OH)_2 / \Delta$  $Ru(3)Cl<sub>3</sub>$  $NH_4PF_6$ DBU / LiCI  $[Ru(3)L](PF_6)_2$  $\overline{\overline{(CH_2OH)_2/A}}$ EtOH /  $\Delta$ 

**Method B** 

 $[Ru(H<sub>2</sub>2)<sub>2</sub>](PF<sub>6</sub>)<sub>2</sub>$  NaH  $R-X$  $NH_4PF_6$  $\blacktriangleright$  [Ru(L')<sub>2</sub>](PF<sub>6</sub>)<sub>2</sub> or [Ru(H4)<sub>2</sub>](PF<sub>6</sub>)<sub>2</sub>  $THF$ 

#### **Method C**

 $\frac{\textsf{NH}_4\textsf{PF}_6}{\textsf{NU}(\textsf{L}')_2\textsf{I}(\textsf{PF}_6)_2}$ DBU / LiCI  $[Rul_2](PF_6)_2$ 

## **Results and Discussion**

**Synthesis.** Although the reaction of  $Ru(DMSO)_4Cl_2^{15}$  with the unsubstituted  $H_2$ **2** in EtOH at reflux<sup>7</sup> was facile, reactions with the disubstituted derivatives, such as **3**, required higher temperatures (Scheme 1). Ethylene glycol at or near the boiling point (method A) gave satisfactory results. Reactions in DMF or DMPU or reactions with RuCl<sub>3</sub> were incomplete, and reactions in DMSO did not proceed at all with hindered ligands. The less hindered, monosubstituted derivatives, such as H**4**, reacted well in ethylene glycol even at lower temperatures. Method A was also useful for the preparation of heteroleptic complexes. Thus,  $RuCl<sub>3</sub>$  was converted to  $Ru(3)Cl<sub>3</sub>$  by a modified literature procedure,<sup>16</sup> then to  $\text{[Ru(3)(H4)]}(PF_6)$  by method A. However, ligands bearing ester groups (**5** and H**6**) suffered extensive transesterification, giving a mixture of products that necessitated a retro-transesterification step (DBU/ LiCl/EtOH)<sup>17</sup> in the workup (method A'). The heteroleptic [Ru- $(3)(5)[PF_6]$ <sub>2</sub> was similarly prepared from Ru $(3)Cl_3$ .

When complexes bearing unsubstituted *N*-H sites were exposed to bases of various potencies (NaOH, CsCO<sub>3</sub>, DBU, NaH), there was an immediate color change from red to green, accompanied by a shift of the MLCT bands toward the red. In most cases, this was entirely reversed upon re-acidification. On alumina TLC plates, this was spontaneous and useful in distinguishing partly N-substituted complexes from fully substituted ones. In air, the H<sub>2</sub>O-soluble  $\text{[Ru(H}_22)_2\text{]Cl}_2^7$  produced

- (10) Downard, A. J.; Honey, G. E.; Steel, P. J. *Inorg. Chem.* **1991**, *30*, 3733.
- (11) Zadykowicz, J.; Potvin, P. G. *J. Org. Chem.* **1998**, *63*, 235.
- (12) Jairam, R.; Lau, K.; Adorante, J.; Potvin, P. G. *Can. J. Chem.* **1999**, submitted.
- (13) Dash, R. M.Sc. Thesis, York University, 1991.
- (14) Jairam, R. M.Sc. Thesis, York University, 1991.
- (15) Evans, I. P.; Spencer, A.; Wilkinson, G. *J. Chem. Soc., Dalton Trans*. **1973**, 204.
- (16) Hadda, T. B.; Le Bozec, H. *Inorg. Chim. Acta* **1993**, *204*, 103.
- (17) Seebach, D.; Thaler, A.; Blaser, D.; Ko, S. Y. *Hel*V*. Chim. Acta* **<sup>1991</sup>**,

the H<sub>2</sub>O-insoluble but CHCl<sub>3</sub>-soluble Ru<sup>III</sup> species [Ru(2)(H2)], which was blue ( $\lambda_{\text{max}}$  538 nm), NMR-silent, and analytically halide-free.13 Although the deprotonated forms of *N*-H-bearing complexes are strongly stabilized by complexation, they remained moderately nucleophilic as they readily reacted with alkylating agents to generate new red products. Thus,  $\text{[Ru(H<sub>2</sub>2)<sub>2</sub>] (PF_6)_2$  was treated with NaH in THF, followed by excess CH<sub>3</sub>I (method B), to afford  $[Ru(3)_2](PF_6)_2$  identical with material prepared from free **3** by method A.18 We also verified that the partially methylated complexes  $\text{[Ru(H4)_2]}(\text{PF}_6)$  and  $\text{Ru(3)}(\text{H4})$ ]- $(PF_6)_2$  also produced the fully methylated  $[Ru(3)_2](PF_6)_2$  by this method. To our knowledge, these are the first instances of such modifications on complexed ligands, although the regioselective functionalizations of free  $H_2$ **2** reported earlier<sup>8,11</sup> depended on transient coordination to Na<sup>+</sup> or  $K^+$ . This reaction enabled us to prepare a number of new derivatives of  $\text{[Ru(H}_2\text{2})_2\text{][PF}_6)_2$ bearing ethyl, benzyl, and esterified acetic acid or *p*-toluic acid side chains. This complexation-alkylation route has certain advantages over the corresponding alkylation-complexation route in that the complexation step is much easier and more convenient with less congested ligands, there is no risk of producing regiomers and there is no risk of transesterification when ester groups are present. The overall yields were higher as well. For instance, ligands **9**<sup>11</sup> and **10**<sup>8</sup> were known and could also produce  $[RuL_2]^{2+}$  complexes by method A, albeit in lower yields than by method B. However, the  $[Ru(7)_2](PF_6)_2$  and  $[Ru (8)_2$ ](PF<sub>6</sub>)<sub>2</sub> produced by method B are complexes of ligands that are unknown in their free states.  $\text{[Ru(H6)_2]}(\text{PF}_6)$ <sub>2</sub> was also similarly methylated on a small scale to help resolve overlaps in the NMR spectra.

A logical application of this complexation-alkylation process is to assemble oligonuclear species. We had earlier<sup>11</sup> identified  $-CH<sub>2</sub>$ - bridges as desirably short linkages between octahedral centers that would favor helicity, i.e. the formation of *like* (chiral racemic) diastereomeric forms of any two-metal fragment of a chain, as opposed to *unlike* (mesoid) forms. We therefore attempted alkylations of  $N$ -H-bearing complexes with  $CH<sub>2</sub>Br<sub>2</sub>$ . Unfortunately, the reaction of  $[Ru(H4)_2](PF_6)_2$  with 1 equiv of  $CH<sub>2</sub>Br<sub>2</sub>$  failed to provide the expected, doubly stranded, binuclear *helicate*, nor did  $[Ru(3)(H4)](PF_6)_2$  produce the desired singly stranded binuclear complex (Scheme 2). Both reactions instead gave complicated mixtures and similar results were obtained with  $CH<sub>2</sub>I<sub>2</sub>$ . NMR analysis of the product mixtures led us to suspect that CH2Br groups were present. Indeed, the reaction of  $\text{[Ru(H4)_2]}(\text{PF}_6)$ <sub>2</sub> with an excess of  $\text{CH}_2\text{Br}_2$  produced the novel bis(bromomethylated)  $[Ru(11)_2](PF_6)_2$ . Although this and the putative *mono*(bromomethylated) intermediate both possess leaving groups, their displacements by the deprotonated species  $[Ru(4)<sub>2</sub>]$ <sup>0</sup> or  $[Ru(4)(11)]$ <sup>+</sup> were perhaps too sterically hindered. The same can be said of the intermediates in the earlier reactions with  $\text{[Ru(H4)_2]}(\text{PF}_6)$ <sub>2</sub> and  $\text{[Ru(3)(H4)]}( \text{PF}_6)$ <sub>2</sub>. There was evidently no anchimeric assistance of the second X<sup>-</sup> displacements at the complexes'  $-CH<sub>2</sub>X$  side chains, in contrast to reactions of free H**4**, which led cleanly to the ditopic ligand  $12^{11}$  even with excess  $CH<sub>2</sub>X<sub>2</sub>$  because of that assistance. Instead,



*74*, 1102. (18) Zadykowicz, J.; Potvin, P. G. *J. Coord. Chem.* **1999**, *47*, 395.

<sup>(9)</sup> Saha, N.; Kar, S. K. *J. Inorg. Nucl. Chem.* **1977**, *39*, 1236. Watson, A. A.; House, D. A.; Steel, P. J. *J. Org. Chem.* **1991**, *56*, 4072. Chabert, N.; Jacquet, L.; Marzin, C.; Tarrago, G. *New J. Chem.* **1995**, *19*, 443. Steel, P. J.; Constable, E. C. *J. Chem. Soc., Dalton Trans.* **1990**, 1389. Lecloux, D. D.; Tolman, W. B. *J. Am. Chem. Soc.* **1993**, *115*, 1153. Jameson, D. L.; Blaho, J. K.; Kruger, K. T.; Goldsby, K. A. *Inorg. Chem.* **1989**, *28*, 4312. Jameson, D. L.; Goldsby, K. A. *J. Org. Chem.* **1990**, *56*, 4072.

**Scheme 2**



the binuclear species  $[(3Ru)_2(12)](PF_6)_4$  was obtained after mild heating of  $12$  with  $Ru(3)Cl<sub>3</sub>$  in ethylene glycol. Higher temperatures caused extensive fragmentation to produce [Ru(**3**)-  $(H4)$ <sup>2+</sup>, quite probably by anchimerically assisted expulsion of  $[Ru(3)(4)]^+$  from a mononuclear intermediate. FAB-MS of  $[(3Ru)<sub>2</sub>(12)](PF<sub>6</sub>)<sub>4</sub>$  showed evidence of a similar fragmentation, with a peak at  $m/z$  780 corresponding to  $[Ru(3)(4)]^+$ .

Carboxy-functionalized complexes were also of interest to us, but they were unfortunately not directly accessible from  $HOOC$ -bearing ligands<sup>11</sup> by method A, giving instead browngreen mixtures even when reacting under an Ar blanket. Instead, the acidic complexes  $[Ru(H_213)_2](PF_6)_2$ ,  $[Ru(H_214)_2](PF_6)_2$ , and  $[Ru(H<sub>2</sub>15)<sub>2</sub>](PF<sub>6</sub>)$ <sub>2</sub> were generated by hydrolyses (DBU/LiCl/ THF/H<sub>2</sub>O)<sup>17</sup> of the corresponding ester-bearing complexes [Ru- $(5)_2$ ](PF<sub>6</sub>)<sub>2</sub>, [Ru(9)<sub>2</sub>](PF<sub>6</sub>)<sub>2</sub>, and [Ru(10)<sub>2</sub>](PF<sub>6</sub>)<sub>2</sub>, respectively (method C).

Although many of the complexes studied here were isolable as their  $Cl^-$  salts—some were partly characterized as such—the PF<sub>6</sub><sup>-</sup> salts were preferred for their greater liposolubilities and chromatographic separabilities. The complexes were characterized by elemental analysis and FAB-MS, as well as  ${}^{1}H$  and  ${}^{13}C$ NMR (see below). In FAB-MS, the ion of highest mass usually resulted from the loss of one counteranion. Lower mass peaks corresponded to further anion loss, and to doubly charged ions. The HOOC-bearing complexes were the most troublesome to purify and characterize. FAB-MS was only successful in glycerol/thioglycerol matrixes. Repeated microanalyses of recrystallized  $\text{[Ru(H<sub>2</sub>13)<sub>2</sub>](PF<sub>6</sub>)<sub>2</sub>$  and  $\text{[Ru(H<sub>2</sub>14)<sub>2</sub>](PF<sub>6</sub>)<sub>2</sub>$  failed to give the expected results, suggesting instead a partial loss of the elements of  $HPF_6$  during recrystallization.

**NMR Spectroscopy and Structure.** The 1H NMR spectra fully supported the formulations and structures of the complexes described herein. In our experience with the in situ binding of Na<sup>+</sup>, Zn<sup>II</sup>, Ti<sup>IV</sup>, or D<sup>+</sup> by our tridentates,  $8,11$  as well as with  $Ru^{II}$  complexes of the bidentate analogues,<sup>4</sup> a comparison of the relative positioning of the pyridine signals from the complexes with that from the free ligands can reveal the regiochemistry of N-substitution and can confirm the formation of a complex through the occurrence of conformational changes about the inter-ring bonds. Thus, *out* N-substitution (i.e. at position 1 according to the indazole numbering) of an unsubstituted (*N*-H-bearing) tetrahydroindazole moiety is signaled by an inversion of the positioning of the pyridine H-3/5 doublet(s) with respect to the H-4 triplet (or doublet of doublets), a relative positioning which reverts to the original situation upon metal or proton binding. There is no such change upon complexation of an *N*-H-bearing moiety. An unsubstituted tetrahydroindazole moiety is held in a syn conformation with respect to the pyridine ring by virtue of H-bonding involving the pyridine N and the

*in* regiomer (i.e. the 2*H* tautomer) of the tetrahydroindazole portion, whereas an *out*-substituted moiety prefers an anti conformation which reverts to the syn conformation upon complexation. The causes of these chemical shift changes have been discussed earlier, and our interpretations have recently been confirmed by crystallography.5,18

In the present work, the complexation of our disubstituted ligands resulted in a change in the pyridine signal pattern entirely consistent with the binding of the metal at all three available nitrogens of an out,out-disubstituted ligand in its syn,syn conformer. The complexation of a monosubstituted ligand caused a shift in pattern that was similarly consistent with a change from a syn,anti conformation to a syn,syn one, with a necessary migration of the N-2-H to produce the 1-tautomer. Subsequent alkylation caused no further change in the signal pattern, but only *out* substitution is possible if the *N*-H-bearing ligand is also bound at its three available nitrogens. That this was indeed so was indicated by the increase in acidity of *N*-Hbearing ligands upon complexation. The formation of the same tetramethylated complex  $\text{[Ru(3)<sub>2</sub>]}^{2+}$  from free 3 as by alkylation of complexed H**4** also confirms this scenario. The crystal structure of  $[Ru(3)<sub>2</sub>]Cl<sub>2</sub>$  has recently been obtained<sup>18</sup> and it confirmed the expected *pseudo*-octahedral coordination, as well as the regiochemistry of substitution and the ring orientations.

<sup>1</sup>H NMR spectroscopy was also useful in specifying the structure of the binuclear complex. As expected, the <sup>1</sup>H NMR spectrum of  $[(3Ru)_212](PF_6)_4$  signaled the *like*, helical diastereomer: There were only two sets of pyridine signals in 1:1 ratio, indicating equivalent units of **4** within the ditopic **12**. There were three  $CH_3$  singlets in 1:1:1 ratio, a situation that implies a symmetric unit of **12** and 2 equiv of an unsymmetric **3** moiety. The environment of each  $3$  is therefore chiral. All  $CH_3$  singlets were strongly shifted upfield, an expected effect of the ring currents of perpendicular ligands (see Scheme 2). The  $CH<sub>2</sub>$ signal, also shifted upfield for the same reason, appeared as a singlet, confirming that the two metal centers had the same chirality. Diastereotopicity would have been expected in the *unlike* form. None was found in  $Zn^{2+}$  or Na<sup>+</sup> complexes either<sup>11</sup> but, in those cases, a rapid interchange between enantiomorphs via free rotation about the  $N-CH_2$  bonds may have occurred. In the present case, the lack of symmetry in the dimethylated ligand **3** proved that there was no exchange of the metal chirality, presumably because of strong steric hindrance to such  $N$ – $CH<sub>2</sub>$  rotation.

An unexpected case of diastereotopicity was observed with the bis(bromomethyl) complex  $\text{[Ru(11)_2]}(\text{PF}_6)$ <sub>2</sub>. In concentrated solution (35 mg/mL), the  $CH<sub>2</sub>Br$  groups were diastereotopic and gave a pair of coupled doublets  $(J = 11 \text{ Hz})$  but gave a singlet in more dilute solution. We postulate that a more intimate

**Table 1.** UV-Vis Absorption Maxima (nm) by  $[Ru(L)_2]^{2+}$  in CH3CN

L	$L \pi \rightarrow \pi^*$	MLCT $\left[\epsilon \times 10^{-3} \,\mathrm{M}^{-1} \,\mathrm{cm}^{-1}\right]$
H <sub>2</sub>	$248 - 314$	414 [25.8]
3	$244 - 324$	418 [16.5]
5	$272 - 320$	424 [20.0]
H <sub>6</sub>	$274 - 322$	420 [13.8]
$6-$	$278 - 350$	446 [10.5]
7	$244 - 324$	$416$ [16.2]
8	$244 - 326$	416 [17.4]
9	$208 - 328$	$416$ [18.1]
10	$250 - 320$	416 [17.0]
13	$272 - 330$	422 [20.8] <sup>a</sup>
14	$208 - 328$	416 $[18.4]$ <sup>a</sup>
15	$250 - 320$	418 $[14.7]$ <sup>a</sup>

*<sup>a</sup>* In methanol.

association of the  $PF_6$ <sup>-</sup> counterions with the complex was occurring in the concentrated solution and that this reduced the mobility of the  $CH<sub>2</sub>Br$  side chains. A similar phenomenon was reported for a terpyridine Ru complex bearing  $-CH<sub>2</sub>N$  side chains: the  $CH<sub>2</sub>$  groups showed <sup>1</sup>H NMR singlets, as expected for freely rotating side chains, but these produced an AB pattern when in the presence of dicarboxylate salts that were engaged in H bonding to the side chains.19

**Electronic Spectra.** In general agreement with the spectra of Ru polypyridine<sup>20</sup> and pyrazolylpyridine<sup>4</sup> complexes, the complexes exhibited two major absorptions (Table 1), one in the 210-330 nm range assigned to ligand-centered  $(\pi \rightarrow \pi^*)$ transitions and the other in the 416-424 nm range assigned to metal-to-ligand charge transfer (MLCT) (d→π<sup>\*</sup>) transitions. The MLCT positions lie intermediate between that with  $\text{[Ru(tpy)_2]}^{2+}$  $(476 \text{ nm})^{21}$  and that of the complex of the N-linked analogue 2,6-di(pyrazol-1-yl)pyridine (dpp)  $(377 \text{ nm})$ .<sup>10</sup> There is a weak substituent effect on the MLCT positions: complexes with aromatic substituents have slightly lower energy MLCT bands  $(420-424 \text{ nm})$  than do those with alkyl substituents  $(416-418 \text{ nm})$ nm), entirely in accord with the expectation that electronwithdrawing groups will lower the ligand  $\pi^*$  levels.<sup>20</sup> The modesty of the effect is probably due to an orientation orthogonal to the pyrazole plane, as was found in our bidentate analogue.<sup>4</sup> Not surprisingly, the binuclear  $[(3Ru)_212]^{4+}$  showed a single but very intense MLCT band at 416 nm ( $\epsilon$  28 900 M<sup>-1</sup>  $cm^{-1}$ ) in CH<sub>3</sub>OH.

In the presence of base, both the  $\pi \rightarrow \pi^*$  and MLCT bands of  $[Ru(H6)_2](PF_6)_2$  shifted toward the red. In agreement with previous descriptions of similar phenomena with *N*-H-bearing complexes,22,23 the lower energy band is likely due to deprotonated form(s) in which  $6^-$  has increased  $\pi$ -donor properties. Similarly, the treatment of a  $CH_3CN$  solution of  $[Ru(H_22)_2]$ - $(PF_6)_2$  with aliquots of Et<sub>3</sub>N (up to 5 equiv) caused the disappearance of the 414 nm band and the appearance of a new, red-shifted MLCT absorption at 434 nm.

**Electrochemistry.** Cyclic voltammetry (CV) plots of fully substituted complexes (Table 2) each revealed a  $Ru^{3+/2+}$  wave

- (19) Goodman, M. S.; Jubian, V.; Hamilton, A. D. *Tetrahed. Lett.* **1995**, 2551.
- (20) Juris, A.; Balzani, V.; Barigelletti, F.; Campagna, S.; Belser, P.; von Zalewsky, A. *Coord. Chem. Re*V*.* **<sup>1988</sup>**, *<sup>84</sup>*, 85.
- (21) Hecker, C. R.; Gushurst, A. K. I.; McMillin, D. R. *Inorg. Chem.* **1991**, *30*, 538.
- (22) Hage, R.; Prins, R.; Haasnoot, J. G.; Reedijk, J. *J. Chem. Soc., Dalton Trans.* **1987**, 1389.
- (23) Sullivan, B. P.; Salmon, D. J.; Meyer, T. J.; Peedin, J. *Inorg. Chem.* **<sup>1978</sup>**, *<sup>17</sup>*, 3334; Belser, P.; von Zelewsky, A. *Hel*V*. Chim. Acta* **<sup>1980</sup>**, *63*, 1675.

**Table 2.** Half-Wave Potentials (V vs SCE),*<sup>a</sup>* Estimated HOMO-LUMO Gaps  $\Delta E$  (V), and  $E$ <sub>L</sub> ligand parameters (V)

complex	$E_{1/2}^{3+/2+}$	$E_{1/2}^{2+/+}$	ΛE	$E_{\rm L}$
$\text{[Ru(3)2]}^{2+}$	$+0.83$	$-1.66^b$	2.49	0.18
$[Ru(5)2]^{2+}$	$+0.93$	$-1.52$	2.45	0.20
$\text{[Ru(9)_2]^{2+}}$	$+0.96$	$-1.53^b$	2.49	0.20
$[(3Ru),12]^{4+}$	$+0.98$	$-1.50^{b}$	2.48	0.23c
$[Ru(3)(H4)]^{2+}$	$+0.71$	$-1.1^{b,d}$		$0.14^{e}$
$[Ru(3)(4)]^+$	$+0.37$			0.03 <sup>f</sup>
$\left[\text{Ru}(\text{H}_2\text{2})_2\right]^{2+\,g}$	$+0.63$			0.15
$[Ru(tpy)2]^{2+h}$	$+1.27$	$-1.27$	2.54	0.26
$[Ru(dpp)_2]^{2+i}$	$+1.25$	$-1.66^{d}$	2.91	0.25
$[Ru(H1)3]^{2+j}$	$+0.93$			0.21
$[Ru(Ar1)3]^{2+ j,k}$	$+1.12$	$-1.66$	2.78	0.22

<sup>*a*</sup> Reversible or quasi-reversible waves scanned at 100 mV s<sup>-1</sup> in  $CH_2Cl_2$  containing 0.1 M <sup>n</sup>Bu<sub>4</sub>NPF<sub>6</sub> at 20  $\pm$  1 °C. <sup>*b*</sup> Estimated. *c* For 12 *d* Irreversible *c* For H4 *f* For 4<sup>-</sup> *s* In DMSO. Several other waves **12**. *<sup>d</sup>* Irreversible. *<sup>e</sup>* For H**4**. *<sup>f</sup>* For **4**-. *<sup>g</sup>* In DMSO. Several other waves were also present (see text). *<sup>h</sup>* Reference 24. *<sup>i</sup>* bpp is 2,6-di(1-pyrazolyl)pyridine from ref 10. *<sup>j</sup>* Reference 4. *<sup>k</sup>* Ar**1** is 1-(4-ethoxycarbonylphenyl)-3-(2-pyridyl)-4,5,6,7-tetrahydroindazole.

and a reversible or quasi-reversible reduction wave and can be compared with results from  $Ru^{II}$  complexes of the N,N'-linkage isomer,<sup>10</sup> of tpy<sup>24</sup> and of the bidentate analogues<sup>4</sup> of  $H_2$ **2** (H1) and of **5** (Ar**1**). The nature of the N-substituents exerted a minor influence but a more important one than had been seen with the bidentate analogues.<sup>4</sup> The  $Ru^{3+/2+}$  waves were at less positive values than with the bidentate analogues which, in turn, were less positive than with  $[Ru(tpy)_2]^{3+/2+}$ , reflecting the pyridine content in each case and signaling higher  $t_{2g}$  levels with increasing pyrazole content. As with the bidentate analogues in relation to  $\left[\text{Ru(bpy)}_3\right]^{2+}$ , our tridentate complexes were reduced at more negative potentials than was  $[Ru(tpy)<sub>2</sub>]^{2+}$ , indicating higher ligand  $\pi^*$  levels and poorer  $\pi$ -accepting properties due to the  $\pi$ -rich pyrazole rings. The parallel increases in both metal-centered HOMO and ligand-centered LUMO resulted in the spreads between oxidation and reduction waves  $(\Delta E = E_{1/2}^{2+\gamma + \gamma} - E_{1/2}^{3+\gamma + \gamma})$  in Table 2 that were a little smaller than with  $[Ru(tpy)_2]^{2+}$ , which is not consistent with the MLCT bands lying at somewhat higher energy. In comparison, the N-linked analogue  $[Ru(dpp)_2]^{2+}$  was oxidized at a potential comparable to that of  $\left[\text{Ru(tpy)}_{2}\right]^{2+}$  but it was reduced at a more negative potential, such that its ∆*E* value was significantly larger.<sup>10</sup> This indicates a comparable  $t_{2g}$  level but a higher ligand  $\pi^*$  level than in  $[Ru(tpy)_2]^{2+}$ , and is consistent with a significantly higher-energy MLCT band (Table 1). In fact, our complexes do not follow the linear relationship between MLCT energies and  $\Delta E$  constituted by  $[Ru(tpy)_2]^{2+}$ ,  $[Ru(dpy)_2]^{2+}$ , and the bidentate complexes  $[Ru(bpy)_3]^2$ <sup>+</sup> and  $[Ru(Ar1)_3]^{2+}$ . It appears that our *C*-linked pyrazolylpyridines are comparable *π* donors but better  $\sigma$  donors than is the N-linked variety. This is consistent with conclusions drawn from crystal structure studies.5,18

The known Lever ligand electrochemical parameters<sup>6</sup>  $E<sub>L</sub>$  and those calculated for the new ligands are included in Table 2. In view of the *E*<sup>L</sup> values of mono(pyrazolyl)pyridine analogues (e.g. H**1**) that are lower than those of the polypyridines, our bis(pyrazolyl)pyridines have understandably even lower values, which are further decreased by electron-donating or H groups or by deprotonation. In contrast, the *N,C*-linkage isomer dpp has a higher *E*<sup>L</sup> value.

 $[Ru(3)(H4)](PF<sub>6</sub>)<sub>2</sub>$  in CH<sub>2</sub>Cl<sub>2</sub> produced a major oxidation wave at  $+0.71$  V vs SCE accompanied by a more minor wave

<sup>(24)</sup> Morris, D. E.; Hanck, K. W.; DeArmond, M. K. *J. Electroanal. Chem.* **1983**, *149*, 115.



**Figure 1.** CV of  $\text{[Ru(3)(H4)](PF_6)_2}$  in  $\text{CH}_2\text{Cl}_2$  showing initial (full line) and steady-state (dotted line) full scans.

**Scheme 3**



at  $+0.37$  V. There were also cathodic peaks near  $-0.65$  and -1.1 V (Figure 1). Haga described pH-dependent variations in oxidation wave intensity ratios for Ru<sup>II</sup> complexes of benzimidazoles and attributed the different waves to different protonation states, $25$  and it is reasonable to analogously attribute the wave at  $+0.71$  V to a standard  $[Ru(3)(H4)]^{3+2+}$  couple and that at  $+0.37$  V to the analogous process with the deprotonated that at  $+0.37$  V to the analogous process with the deprotonated form, i.e.  $[Ru(3)(4)]^{2+/+}$ , undergoing slow proton exchange.

If the sample was not scanned to negative potentials, the intensities of the two oxidation waves were stable but, upon cycling to negative potentials, the more positive wave decreased in intensity while that at  $+0.37$  V increased (Figure 1). Hage et al. witnessed a similar phenomenon with  $\text{[Ru(bpy)<sub>2</sub>(HL)]}^{2+}$ species where HL is an *N*-H-bearing triazolylpyridine:<sup>22</sup> after cycling negative through the reduction wave, a second, less positive oxidation wave appeared and became dominant. These authors explained that the reduced form  $\text{[Ru}^{\text{II}}(\text{bpy})_2(\text{HL}^{-})$ <sup>+</sup> lost H<sup>+</sup> but did not explain how the product,  $[Ru^{II}(bpy)_2(L^{*2-})]^0$ , was reoxidized to  $[Ru^{II}(bpy)<sub>2</sub>(L^-)]^+$  before further oxidation to  $[Ru^{III}(bpy)_{2}(L^{-})]^{+2}$  at the new oxidation wave. The reoxidation of  $[Ru^{II}(bpy)_{2}(L^{\bullet 2})]$ <sup>0</sup> should have occurred at a less negative potential than the corresponding reoxidation of  $[Ru^{II}(bpy)_{2}$ - $(HL^{\bullet-})$ <sup>+</sup>. Further, it is counterintuitive that H<sup>+</sup> should be lost upon reduction when the oxidized forms should be stronger acids. In the present case, we reason that scanning negative caused a change in the intensity ratio by effecting a shift in the  $H<sup>+</sup>$  mass balance: a shift toward the deprotonated form indicates a net loss of  $H^+$ , which can be rationalized, as in Scheme 3, by loss of H<sup>•</sup> upon reduction of ligated H4. The product  $\left[\text{Ru}^{\text{II}}(3)-\right]$  $(4)$ <sup>+</sup> is reoxidized only at +0.37 V.

Similar but more complicated events occurred with [Ru-  $(H_22)_2$ <sup>2+</sup> in DMSO. CV revealed a major, well-defined oxidation wave at  $+0.63$  V vs SCE with three smaller waves at  $+0.46$ ,  $+0.10$  and  $-0.21$  V vs SCE and an initial cathodic peak current ratio of about 6.9:2.8:2.0:1.5. No distinct reduction wave was detected to the negative potential limit  $(-1.49 \text{ V})$ . On the anodic scan, the intensities of the two most positive waves decreased while those of the two least positive waves increased. This continued upon repeated cycling until a fairly stable cathodic current ratio of 4.1:2.4:2.4:2.1 was achieved. If, in analogy to the previous case, H• was lost at negative potentials, then, unlike the previous, heteroleptic case, no reoxidation peak was expected and none was seen.

**Supramolecular Interactions.** When  $\text{[Ru(H}_213)_2\text{][PF}_6)$ <sub>2</sub> in  $CH<sub>3</sub>CN$  was treated with aliquots of Et<sub>3</sub>N (up to 5 equiv), no change was seen in the UV-visible spectra but the  ${}^{1}H$  NMR signals in  $CD_3CN$  were strongly broadened and new broad signals appeared. We suspect that deprotonated forms acted as counterions in supramolecular assemblies that, because of the increased mass, suffered faster relaxation and line broadening. A literature report of supramolecular H bonding between  $dicarboxulate$  ions and a  $Ru<sup>II</sup>$  terpyridine complex bearing thioureido side chains also cites pronounced line broadening with little change in the positions of the terpyridine NMR signals.19 Pronounced broadening was also observed with the  $PF_6^-$  salt of methyl viologen (MV<sup>2+</sup>) in the presence of Et<sub>3</sub>N, though there was no sign of the cation radical ( $\lambda_{\text{max}}$  607,  $\epsilon$ 13 900  $M^{-1}$  cm<sup>-1</sup>).<sup>26</sup> This may have been due to  $PF_6$ <sup>-</sup>/OH<sup>-</sup> exchange arising from traces of water. When a mixture of[Ru-  $(H<sub>2</sub>13)<sub>2</sub>$ ](PF<sub>6</sub>)<sub>2</sub> and MV(PF<sub>6</sub>)<sub>2</sub> was similarly titrated, there were no detectable spectral changes absent with the controls, but ><sup>2</sup> equiv of  $Et_3N$  produced a precipitate from  $CH_3CN$  and the supernatant was depleted of the Ru complex. The isolated red solid was insoluble in organic solvents. Its <sup>1</sup>H NMR spectrum in  $D_2O$ , which is expected to destroy any supramolecular association, showed signals for the intact Ru species and  $MV^{2+}$ in a reproducible 2:1 molar ratio, indicating that the precipitation was of a salt of formulation  $(MV)[Ru(H13)(13)]_2$  (Figure 2). Unfortunately, all attempts at recrystallizing this precipitate from H2O produced powders, but further characterization is underway.

In contrast, analogous titrations with  $\text{[Ru(H<sub>2</sub>2)<sub>2</sub>](PF<sub>6</sub>)<sub>2</sub> pro$ duced no precipitate and the resulting spectra were the simple superpositions of the control spectra. We conclude that the deprotonated forms of  $[Ru(H<sub>2</sub>2)<sub>2</sub>](PF<sub>6</sub>)<sub>2</sub>$  do not engage in significant interactions with  $MV^{2+}$ .

## **Experimental Section**

**General.** Ru( $\text{DMSO}_{4}Cl_{2}$  was prepared by a literature method.<sup>15</sup> Anhydrous ethylene glycol and DMF were from Aldrich. THF was distilled over K and benzophenone. DMSO was dried (CaO) and distilled over molecular sieves (5 Å) and was then frozen and stored in sealed vials under Ar. Other solvents were reagent grade and used without drying or purification. The petroleum ether (PE) used was the light fraction (bp 30-<sup>60</sup> °C). Cyclic voltammetry (CV) was performed using a Pine Instruments RDE-3 potentiostat. A conventional threeelectrode cell was used in all experiments. The working electrode was a Pt disk (0.196 mm2), and the quasi-reference electrode was Ag/AgCl wire. A Pt wire was used as a counter electrode. Ferrocene was added at the end of each experiment, and its reference potential was taken as  $+0.450$  V vs SCE in CH<sub>2</sub>Cl<sub>2</sub> and  $+0.50$  V vs SCE in DMSO.<sup>27</sup> UVvisible spectra were recorded with a Hewlett-Packard 8452A diode array spectrophotometer. NMR spectra were obtained on a 400-MHz Bruker AMX instrument in CD<sub>3</sub>CN, unless otherwise indicated. Mass spec-

<sup>(25)</sup> Haga, M.-A. *Inorg. Chim. Acta* **1983**, *75*, 29.

<sup>(26)</sup> Watanabe, T.; Honda, K. *J. Phys. Chem.* **1982**, *86*, 2617. (27) Lever, A. B. P. *Inorg. Chem.* **1978**, *17*, 1146.



**Figure 2.** Proposed salt of formulation (MV)[Ru(H**13**)(**13**)]2.

troscopy was carried out in FAB mode by Dr. B. Khouw on a Kratos Profile machine. Peak intensities are reported as a percentage of the base peak intensity. Microanalyses were performed by Guelph Chemical Laboratories Ltd. (Guelph, ON), National Chemical Consulting Inc. (Tenafly, NJ), or Canadian Microanalytical Services (Delta, BC).

**Method A: Synthesis of**  $\text{[Ru(H<sub>2</sub>2)<sub>2</sub>](PF<sub>6</sub>)<sub>2</sub>$ **.** A mixture of H<sub>2</sub>**2** (0.783) g, 2.45 mmol) and  $Ru(DMSO)_4Cl_2$  (0.595 g, 1.225 mmol) was heated to reflux under Ar in 20 mL of anhydrous ethylene glycol for 3 days. After cooling, the reaction mixture was treated with an aqueous solution containing a slight excess of  $NH_4PF_6$  (0.408 g, 2.5 mmol) and stirred for 20 min. An orange-red precipitate formed instantanously. After cooling in the refrigerator for 1 h, filtration and vacuum-drying produced the red  $\text{[Ru(H<sub>2</sub>2)<sub>2</sub>](PF<sub>6</sub>)<sub>2</sub>$  in quantitative yield. Its spectra were identical to those of the Cl<sup>-</sup> salt previously reported.<sup>7</sup> Anal. Calcd for C38H42N10P2F12Ru'2H2O: C, 42.82; H, 4.35; N, 13.14. Found: C, 42.96; H, 3.97; N, 13.14.

**Method A':** Synthesis of  $\left[\text{Ru}(5)_2\right]\left(\text{PF}_6\right)$ , Method A was first followed, using diester  $5$  (0.205 g, 0.33 mmol) and  $Ru(DMSO)_4Cl_2$ (0.080 g, 0.165 mmol). The reaction mixture was treated with aqueous saturated solution of NaCl and extracted into CHCl<sub>3</sub>. After removal of the solvent, the dark-red oil was vacuum-dried and was then redissolved in 20 mL EtOH and treated with DBU (0.100 g, 0.66 mmol) and LiCl (0.140 g, 3.3 mmol). After 48 h at reflux, the EtOH was removed and the remaining yellow oil was triturated with dilute HCl and extracted into CHCl<sub>3</sub>. Removal of the solvent afforded a red solid,  $Ru(5)_2Cl_2$ , which was purified by column chromatography on silica gel, using CHCl3/MeOH (90:10) as eluent. After collecting the appropriate fractions and liberating them of solvents, the red solid residue was dissolved in MeOH and treated with excess  $NH_4PF_6$  in  $H_2O$  to produce the brick-red Ru(5)<sub>2</sub>(PF<sub>6</sub>)<sub>2</sub> (0.224 g, 84%). <sup>1</sup>H NMR (acetone-*d*<sub>6</sub>): δ 1.48 (t, 12H,  $J = 7.0$  Hz), 1.80 (m, 8H), 1.94 (m, 8H), 2.32 (m, 8H), 3.03 (m, 8H), 4.48 (q, 8H,  $J = 7.0$  Hz) 6.84 (d, 8H,  $J = 8.0$  Hz) 7.51  $(d, 4H, J = 7.0 \text{ Hz})$ , 7.59 (t, 2H  $J = 7.2 \text{ Hz}$ ), 7.72 (d, 8H,  $J = 8.0 \text{ Hz}$ ) ppm. 13C NMR: *δ* 14.54, 21.42, 22.08, 22.50, 62.42, 118.92, 120.38, 127.30, 130.80, 133.36, 136.28, 139.46, 147.57, 151.92, 154.32, 157.68, 162.05, 165.70, 168.80 ppm. MS *m*/*z* (%) 1622 (4, M), 1477 (100, M  $-$  PF<sub>6</sub>), 1332 (50, M  $-$  2PF<sub>6</sub>), 666 (57, (M  $-$  2PF<sub>6</sub>)/2). Anal. Calcd for  $C_{74}H_{74}N_{10}O_8P_2F_{12}Ru \cdot 2H_2O$ : C, 53.59; H, 4.74; N, 8.45. Found: C, 53.73; H, 4.59; N, 8.50.

**Method B: Synthesis of**  $\text{[Ru(3)_2]}\text{ (PF}_6)$ **, Solid NaH (0.019 g, 0.8)** mmol) was added to a solution of  $Ru(H<sub>2</sub>2)<sub>2</sub>(PF<sub>6</sub>)<sub>2</sub>$  (0.103 g, 0.1 mmol) in dry THF.  $H_2$  evolution was immediate and the solution turned green. The mixture was kept under Ar for 2 h and was then treated with CH3I (0.071 g, 0.5 mmol) and brought to reflux for 24 h, during which time the color gradually changed to red. After the THF was removed, the red solid residue was dissolved in CHCl<sub>3</sub> and washed with H<sub>2</sub>O. The organic layer was evaporated and the solid red residue was chromatographed on alumina, using  $CH_2Cl_2-MeOH$  (90:10) as eluent, then reprecipitated as its solid red  $PF_6^-$  salt as in method A. Yield 0.100 g (92%). The mp and NMR spectra were identical to those reported for material prepared by method A.18

**Method C: Synthesis of**  $\text{[Ru(H$_2 13)_2](PF$_6)_2}$ **.** A solution of  $\text{Ru(5)_2Cl}_2$ (0.014 g, 0.001 mmol) in 5 mL of THF was treated with 2 drops of H2O, DBU (0.001 g, 0.007 mmol), and LiCl (0.002 g, 0.047 mmol) and allowed to stand for 4 h. A red precipitate formed and the solution became clear. The precipitate was filtered off and washed with CHCl<sub>3</sub>, H<sub>2</sub>O, and Et<sub>2</sub>O. This provided  $Ru(H_213)_2Cl_2$  in quantitative yield. Additional purification was carried out by anion exchange as described in method A. 1H NMR (DMSO-*d*6): *δ* 1.73 (m, 8H), 1.86 (m, 8H), 2.24 (m, 8H), 2.24 (m, 8H), 2.87 (m, 8H), 6.68 (d, 8H,  $J = 7.59$  Hz), 7.34 (m, 12H), 7.55 (d, 8H,  $J = 7.56$  Hz) ppm. <sup>13</sup>C NMR (DMSO- $d_6$ ): *δ* 20.28, 21.09, 21.38, 21.53, 117.45, 119.23, 126.44, 129.72, 132.67, 134.96, 137.96, 146.10, 150.54, 152.75, 166.12 ppm. MS *m*/*z* (%) 1365  $(20, M - PF_6)$ , 1220 (100, M - 2PF<sub>6</sub>), 610 (37, (M - 2PF<sub>6</sub>)/2). Anal. Calcd for  $C_{66}H_{58}N_{10}O_8P_2F_{12}Ru$ : C, 52.49; H, 3.87; N, 9.27. Found: C, 54.88; H, 4.30; N, 9.51.

**Ru(3)Cl3.** In a modification of the procedure of Hadda et al*.*, <sup>16</sup> ligand **3** (0.70 g, 2.01 mol) and RuCl<sub>3</sub> hydrate (0.416 g, 2.01 mol) were dissolved in 35 mL of absolute EtOH and heated to reflux overnight. After removal of solvent, the crude residue was washed with  $H_2O$  and extracted into CHCl<sub>3</sub>. The CHCl<sub>3</sub> phase was washed with  $H_2O$  several times to remove purple and green impurities, leaving a dark brown solution. After removing the CHCl<sub>3</sub>, the residue was redissolved in acetone and treated with Et<sub>2</sub>O. The dark brown precipitate was vacuumdried, leaving 0.78 g of Ru(3)Cl<sub>3</sub> (70%). MS  $m/z$  (%) 519 (1, M -Cl), 483 (10,  $M - 2Cl$ ). Anal. Calcd for  $C_{21}H_{25}N_5Cl_3Ru$ : C, 45.46; H, 4.54; N, 12.62. Found: C, 45.36; H, 4.33; N, 12.45.

 $\textbf{[Ru(H4)_2]}(\textbf{PF}_6)_2$ . This was prepared by method A, using 0.034 g of H4 (0.102 mmol) and 0.025 g of Ru(DMSO)<sub>4</sub>Cl<sub>2</sub> (0.051 mmol) and heating for 2 days. The crude, red oily product was purified by column chromatography on silica gel, using MeOH $-CH_2Cl_2$  (15:85) as eluent, to provide  $0.035$  g of red solid  $\text{[Ru(H4)_2]Cl}_2$  (82%). Anion exchange provided  $[Ru(H4)_2](PF_6)_2$  in quantitative yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$ 1.71 (m, 4H), 1.80 (m, 12H), 2.45 (m, 4H), 2.52 (m, 2H), 2.57 (m, 2H), 2.71 (s, 6H), 2.85 (m, 4H), 2.97 (m, 2H), 3.10 (m, 2H), 7.92 (d, 2H,  $J = 7.8$  Hz), 7.98 (d, 2H,  $J = 7.9$  Hz), 8.08 (t, 2H,  $J = 7.87$  Hz), 10.23 (s, 2H) ppm. 13C NMR (CDCl3): *δ* 20.58, 21.03, 21.44, 21.52, 21.65, 21.89, 22.17, 33.92, 116.73, 118.25, 119.08, 120.02, 136.67, 143.03, 144.80, 149.45, 149.82, 153.75, 154.23 ppm. MS *m*/*z* (%) 912 (18, M - PF<sub>6</sub> - H), 767 (100, M - 2PF<sub>6</sub> - 2H). Anal. Calcd for C40H46N10P2F12Ru'H2O: C, 44.66; H, 4.50; N, 13.02. Found: C, 44.77; H, 4.37; N, 12.75.

 $\textbf{[Ru(3)(H4)]Cl}_2$  **and**  $\textbf{[Ru(3)(H4)](PF}_6)_2$ **.** By method A, Ru(3)Cl<sub>3</sub> (0.100 g, 0.18 mmol) and ligand H**4** (0.060 g, 0.18 mmol) were allowed to react for 3 days. Column chromatography on silica gel, using MeOH-CH<sub>2</sub>Cl<sub>2</sub> (15:85) as eluent, provided 0.085 g of the red solid [Ru(**3**)(H**4**)]Cl2 (55%). 1H NMR: *δ* 1.72 (m, 16H), 2.49 (m, 8H), 2.65 (s, 6H), 2.69 (s, 3H), 8.01 (m, 4H), 8.09 (m, 2H) ppm. 13C NMR: *δ* 21.40, 22.11, 22.22, 22.29, 22.65, 23.26, 23.85, 34.37, 34.72, 118.50, 119.59, 120.39, 136.97, 137.16, 144.48, 149.76, 150.31, 154.77, 155.06, 155.87 ppm. MS *<sup>m</sup>*/*<sup>z</sup>* (%) 817 (4, M - Cl), 781 (100, M - 2Cl), 391  $(5, (M - 2Cl)/2)$ . Subsequently,  $[Ru(3)(H4)](PF_6)$ <sub>2</sub> was obtained as a red solid in quantitative yield. 1H NMR: *δ* 1.81 (m, 16H), 2.50 (m, 8H), 2.64 (s, 6H), 2.69 (s, 3H), 2.98 (m, 8H), 8.11 (m, 4H), 8.19 (m, 2H) 10.81 (s, 1H) ppm. 13C NMR: *δ* 21.06, 21.41, 22.11, 22.60, 23.26, 23.85, 34.53, 34.85, 119.02, 120.33, 120.70, 137.16, 137.58, 144.68, 145.05, 149.57, 150.53, 154.95, 155.27 ppm. MS *m*/*z* (%) 926 (36,  $M - PF_6 - H$ ), 779 (100,  $M - 2PF_6 - 2H$ ). Anal. Calcd for

 $C_{41}H_{48}N_{10}P_2F_{12}Ru \cdot H_2O$ : C, 45.18; H, 4.62; N, 12.85. Found: C, 45.13; H, 4.58; N, 12.74.

 $\textbf{[Ru(3)(5)]Cl}_2$  **and**  $\textbf{[Ru(3)(5)](PF}_6)$ . Using method A', Ru(3)Cl<sub>3</sub> (0.055 g, 0.1 mmol) and diester **5** (0.062 g, 0.1 mmol) were heated to reflux for 3 d. Retro-transesterification was followed by column chromatography on silica gel, using MeOH $-CH_2Cl_2$  (15:85) as eluent, yielding  $0.065$  g of pure, red  $[Ru(3)(5)]Cl_2(57%)$ . <sup>1</sup>H NMR (CDCl<sub>3</sub>): *δ* 1.47 (t, 6H, *J* = 7.16 Hz), 1.59 (m, 4H), 1.88 (m, 12H), 2.13 (m, 4H), 2.64 (m, 4H), 2.79 (m, 4H), 2.83 (s, 6H), 3.06 (m, 4H), 4.46 (q, 4H,  $J = 7.17$  Hz), 6.45 (d, 4H,  $J = 8.19$  Hz), 6.96 (d, 2H,  $J = 7.81$ Hz), 7.17 (t, 1H,  $J = 7.83$  Hz), 7.53 (d, 4H,  $J = 8.12$  Hz), 8.15 (m, 3H) ppm. 13C NMR (CDCl3): *δ* 14.43, 20.07, 21.01, 21.35, 21.43, 21.54, 21.95, 34.26, 61.69, 117.14, 117.22, 118.80, 119.94, 121.49, 126.92, 129.88, 132.29, 136.73, 138.87, 145.46, 147.37, 148.56, 149.84, 154.15, 154.38, 165.05 ppm. This was further characterized as [Ru-  $(3)(5)[PF_6)_2$ . MS  $m/z$  (%) 1354 (8, M), 1208 (100, M - PF<sub>6</sub> - H), 1062 (25, M - 2PF<sub>6</sub> - 2H). Anal. Calcd for  $C_{58}H_{62}N_{10}O_4P_2F_{12}Ru$ 0.5H2O: C, 51.10; H, 4.66; N, 10.27. Found: C, 51.02; H, 4.56; N, 10.08.

**[(3Ru)212](PF6)4.** Ditopic ligand **12** (0.215 g, 0.317 mmol) and Ru- (**3**)Cl3 (0.352 g, 0.634 mmol) in 15 mL of ethylene glycol were heated at 140° for 5 days. The reaction mixture was treated with saturated aqueous NaCl and extracted with CHCl3. An insoluble red film was observed on the walls of the separatory funnel. The CHCl<sub>3</sub> layer was separated, the solvent was removed, the residue was dissolved in MeOH, and the crude product was precipitated as its  $PF_6^-$  salt as before. The red film was dissolved in MeOH and separately treated with NH<sub>4</sub>PF<sub>6</sub> as before. The red solids so obtained were washed with  $H_2O$  and purified by chromatography on silica gel, using  $1:9 \text{ MeOH}-\text{CH}_2\text{Cl}_2$ as eluent. This produced 0.307 g (45%) of the binuclear complex which was recrystallized from acetone - H<sub>2</sub>O. <sup>1</sup>H NMR:  $\delta$  0.25 (m, 2H), 0.54<br>(m, 2H), 0.93 (m, 4H), 1.30 (m, 6H), 1.36 (m, 4H), 1.76 (m, 8H), 2.40 (m, 2H), 0.93 (m, 4H), 1.30 (m, 6H), 1.36 (m, 4H), 1.76 (m, 8H), 2.40 (s, 6H), 2.42 (m, 6H), 2.51 (m, 6H), 2.55 (m, 4H), 2.59 (s, 6H), 2.72 (s, 6H), 2.75 (m, 4H), 3.00 (m, 2H), 3.15 (m, 2H), 3.30 (m, 2H), 4.19  $(s, 2H)$ , 7.87 (d, 2H,  $J = 8.12$  Hz), 7.97 (t, 2H,  $J = 7.92$  Hz), 8.15 (m, 6H), 8.24 (t, 2H, *J* = 7.90 Hz) ppm. <sup>13</sup>C NMR: δ 20.00, 21.34, 21.88, 22.16, 22.49, 22.80, 33.82, 34.56, 34.77, 62.26, 118.63, 119.06, 119.77, 121.26, 121.52, 121.73, 122.18, 137.94, 138.13, 145.61, 145.71, 145.90, 146.09, 149.20, 149.47, 149.76, 151.15, 154.70, 155.13, 155.23 ppm. MS  $m/z$  (%) 2010 (1, M - PF<sub>6</sub> - H), 780 (10, [Ru(3)(4)]<sup>+</sup>). Anal. Calcd for  $C_{83}H_{96}N_{20}P_4F_{24}Ru_2\cdot CH_3COCH_3\cdot H_2O$ : C, 46.28; H, 4.70; N, 12.55. Found: C, 46.21; H, 4.69; N, 12.32.

 $\textbf{[Ru(H6)_2]}$  $\textbf{(PF}_6)$ <sub>2</sub>. Method A' was followed, using monoester H6  $(0.072 \text{ g}, 0.154 \text{ mmol})$ , Ru $(DMSO)_4Cl_2$   $(0.037 \text{ g}, 0.077 \text{ mmol})$  and heating to reflux for 3 days. After transesterification, column chromatography on silica gel, using MeOH-CH<sub>2</sub>Cl<sub>2</sub> (10:90), and anion exchange provided pure red  $\text{[Ru(H6)_2](PF_6)_2}$  (0.033 g, 33%). <sup>1</sup>H NMR: δ 1.55 (t, 6H,  $J = 6.96$  Hz), 1.76 (m, 8H), 1.85 (m, 4H), 1.93 (m, 4H), 2.23 (m, 2H), 2.48 (m, 6H), 2.89 (m, 6H), 3.02 (m, 2H), 4.53  $(q, 4H, J = 6.97 \text{ Hz})$ , 6.36 (m, 2H), 6.71 (m, 2H), 7.58 (m, 4H), 7.87 (m, 6H) ppm. 13C NMR: *δ* 14.61, 21.37, 21.47, 22.14, 22.30, 22.61, 22.83, 62.45, 118.68, 118.80, 120.10, 120.15, 127.42, 130.52, 133.31, 136.58, 139.66, 144.96, 146.04, 150.48, 151.68, 153.90, 154.69, 165.70 ppm. MS  $m/z$  (%) 1181 (9, M – PF<sub>6</sub>), 1036 (100, M – 2PF<sub>6</sub>), 518 (42,  $(M - 2PF_6)/2$ ). Anal. Calcd for  $C_{56}H_{58}N_{10}O_4P_2F_{12}Ru·2C_2H_6O$ : C, 54.88; H, 4.84; N, 9.89. Found: C, 50.75; H, 4.65; N, 9.93.

 $\textbf{[Ru(7)_2]}\textbf{(PF}_6)$ <sub>2</sub>. Method B was followed, using 0.019 g of NaH (0.8) mmol), 0.103 g of Ru(H<sub>2</sub>2)<sub>2</sub>(PF<sub>6</sub>)<sub>2</sub> (0.1 mmol), and 10 mL of EtBr, and heating to reflux for 24 h. Anion exchange as before afforded [Ru-  $(7)_2$ ](PF<sub>6</sub>)<sub>2</sub> in quantitative yield. <sup>1</sup>H NMR (acetone- $d_6$ ):  $\delta$  0.54 (t, 12H, *J* = 7.02 Hz), 1.82 (m, 16H), 2.63 (m, 8H), 3.09 (m, 8H), 3.24 (q, 8H, *J* = 7.47 Hz), 8.37 (d, 4H, *J* = 7.88 Hz), 8.46 (t, 2H, *J* = 7.38 Hz) ppm. 13C NMR: *δ* 15.19, 21.42, 21.88, 22.11, 22.45, 44.72, 119.57, 120.65, 138.41, 145.07, 149.96, 155.58 ppm. MS *m*/*z* (%) 996 (100,  $M - H - PF_6$ , 850 (27,  $M - 2H - 2PF_6$ ). Anal. Calcd for C46H58N10P2F12Ru: C, 48.38; H, 5.12; N, 12.26. Found: C, 48.00; H, 5.10; N, 12.13.

**[Ru(8)2](PF6)2.** By Method B, 0.020 g of NaH (0.8 mmol), 0.103 g of Ru $(H_2^2)_2(PF_6)_2$  (0.1 mmol), and 0.086 g of benzyl bromide (0.5) mmol) were used with overnight heating at reflux. Purification was carried out by column chromatography on silica gel, using first MeOH-  $CH_2Cl_2$  (5:95) to remove the unreacted benzyl bromide then MeOH- $CH_2Cl_2$  (10:90) to collect  $[Ru(8)_2]Cl_2$ , followed by anion exchange as before to give 0.120 g (86%) of red solid. 1H NMR: *δ* 1.72 (m, 16H),  $2.27$  (m, 8H),  $2.57$  (m, 8H),  $4.28$  (s, 8H),  $5.91$  (d, 8H,  $J = 7.40$  Hz), 7.04 (t, 8H,  $J = 7.62$  Hz), 7.21 (t, 4H,  $J = 7.26$  Hz), 7.63 (d, 4H,  $J =$ 7.94 Hz), 8.03 (t, 2H,  $J = 7.91$  Hz) ppm. <sup>13</sup>C NMR:  $\delta$  21.31, 21.71, 22.38, 24.79, 51.45, 119.40, 120.94, 124.53, 128.35, 129.26, 135.46, 137.50, 145.94, 150.32, 154.81 ppm. MS *<sup>m</sup>*/*<sup>z</sup>* (%) 1244 (100, M - <sup>H</sup>  $-$  PF<sub>6</sub>), 1100 (30, M  $-$  2PF<sub>6</sub>), 550 (40, (M  $-$  2PF<sub>6</sub>)/2). Anal. Calcd for C66H66N10P2F12Ru: C, 57.02; H, 4.78; N, 10.07. Found: C, 57.36; H, 4.50; N, 9.70.

 $\textbf{[Ru(9)_2]}(\textbf{PF}_6)$ <sub>2</sub>. Method B was followed, using 0.024 g of NaH (1.0) mmol), 0.120 g of Ru(H<sub>2</sub>2)<sub>2</sub>(PF<sub>6</sub>)<sub>2</sub> (0.12 mmol), and 0.260 g of methyl 4-(bromomethyl)benzoate (1.13 mmol), and heating at reflux for 48 h. Purification consisted of washing the crude chloride salt with  $Et<sub>2</sub>O$  and precipitation of the  $PF_6^-$  salt as before. This yielded 0.190 g of the red [Ru(9)<sub>2</sub>](PF<sub>6</sub>)<sub>2</sub> (98%). <sup>1</sup>H NMR: δ 1.67 (m, 16H), 2.27 (m, 8H), 2.48  $(m, 8H), 3.89$  (s, 12H), 4.33 (s, 8H), 6.02 (d, 8H,  $J = 8.02$  Hz), 7.60  $(d, 4H, J = 7.98 \text{ Hz})$ , 7.66  $(d, 8H, J = 8.37 \text{ Hz})$ , 8.04  $(t, 2H, 7.65 \text{ Hz})$ ppm. 13C NMR: *δ* 21.24, 21.67, 22.10, 51.48, 52.73, 119.49, 121.35, 124.92, 130.29, 130.33, 137.89, 140.59, 146.35, 150.50, 154.61, 167.02 ppm. MS  $m/z$  (%) 1476 (100, M – H – PF<sub>6</sub>), 1330 (71, M – 2H –  $2PF_6$ ), 665 (85, (M – 2H – 2PF<sub>6</sub>)/2). Anal. Calcd for  $C_{74}H_{74}N_{10}O_8P_2F_{12}$ Ru: C, 54.73; H, 4.60; N, 8.63. Found: C, 56.66; H, 4.71; N, 7.37.

 $\textbf{[Ru(10)_2]}\textbf{(PF}_6)_2$ . Following method B, 7 mg of NaH (0.3 mmol), 0.052 g of  $Ru(H<sub>2</sub>2)<sub>2</sub>(PF<sub>6</sub>)<sub>2</sub>$  (0.050 mmol), and 0.043 g of ethyl iodoacetate (0.20 mmol) were used with 24 h heating at reflux. Column chromatography on silica gel using  $MeOH-CH<sub>2</sub>Cl<sub>2</sub>$  (10:90) and anion exchange as before yielded red  $\text{[Ru(10)_2](PF_6)_2}$ , which was recrystallized from acetone – H<sub>2</sub>O (0.056 g, 81%). <sup>1</sup>H NMR:  $\delta$  1.14 (t, 12H,  $J = 7.1$ <br>Hz) 1.83 (m, 16H) 2.44 (m, 8H) 2.98 (m, 8H) 3.78 (s, 8H) 3.85 (g Hz), 1.83 (m, 16H), 2.44 (m, 8H), 2.98 (m, 8H), 3.78 (s, 8H), 3.85 (q, 8H,  $J = 6.99$  Hz), 8.01 (d, 4H,  $J = 7.98$  Hz), 8.16 (t, 2H,  $J = 7.95$ Hz) ppm. 13C NMR: *δ* 13.88, 21.22, 21.69, 48.94, 61.81, 118.44, 119.68, 136.83, 146.40, 148.92, 154.62, 165.40 ppm. MS *m*/*z* (%) 1228  $(100, M - H - PF_6), 1082 (35, M - 2H - 2PF_6), 541 (47, (M - 2H$  $-$  2PF<sub>6</sub> $/2$ ). Anal. Calcd for C<sub>54</sub>H<sub>66</sub>N<sub>10</sub>O<sub>8</sub>P<sub>2</sub>F<sub>12</sub>Ru•H<sub>2</sub>O•CH<sub>3</sub>COCH<sub>3</sub>: C, 47.21; H, 5.14; N, 9.66. Found: C, 47.14; H, 4.91; N, 9.36.

 $\textbf{[Ru(11)_2]}\textbf{(PF}_6)_2$ . Using method B, with 0.066 g of  $\textbf{[Ru(H4)_2]}\textbf{(PF}_6)_2$ (0.06 mmol), 0.005 g of NaH (0.21 mmol) in 25 mL of  $CH_2Br_2$  was heated at reflux for 24 h. The removal of solvent and subsequent washing of the product with CHCl3/H2O gave a dark red solid, which was purified by silica gel chromatography, using  $CH_2Cl_2-MeOH$  (95: 5) as eluent, followed by anion exchange to give  $[Ru(11)_2](PF_6)_2$  as a red solid (0.058 g, 78%). <sup>1</sup> H NMR (35 mg/mL): *δ* 1.81 (m, 16H), 2.48 (m, 4H), 2.56 (m, 4H), 2.63 (s, 6H), 2.98 (m, 8H), 4.71 (d, 2H,  $J = 11.0$  Hz), 4.85 (d, 2H,  $J = 11.0$  Hz), 8.35 (m, 6H) ppm. <sup>13</sup>C NMR: *δ* 21.39, 21.76, 22.15, 22.53, 34.42, 41.62, 119.39, 121.41, 121.70, 122.11, 138.46, 145.90, 146.68, 150.07, 153.61, 154.92, 155.74 ppm. MS  $m/z$  (%) 1096 (24, M - 2PF<sub>6</sub> - 2H). Anal. Calcd for  $C_{42}H_{48}N_{10}Br_2P_2F_{12}Ru^{1/2}C_4H_{10}O: C, 41.26; H, 4.17; N, 10.94. Found:$ C, 41.03; H, 4.39; N, 10.86.

 $\textbf{[Ru(H_214)_2]}(\textbf{PF}_6)_2$ . By method C, using 0.051 g of  $\text{[Ru(9)_2]}(\text{PF}_6)_2$ (0.031 mmol) in THF and a mixture of LiCl (0.026 g, 0.62 mmol), DBU (0.049 g, 0.32 mmol), and  $H_2O$  (0.100 g) in 4 mL of THF, were heated at reflux for 4 days. After removal of THF, the oily residue was dissolved in H2O and acidified with dilute HCl. The dark red solid formed was collected, redissolved in MeOH-H2O, and subjected to anion exchange as before. The  $PF_6^-$  salt was washed with  $H_2O$  and CHCl<sub>3</sub>, then vacuum-dried to yield 0.036 g of the red  $\text{[Ru(H}_2\textbf{14})_2\text{][PF}_6)$ <sub>2</sub> (74%). <sup>1</sup> H NMR (DMSO-*d*6): *δ* 1.60 (m, 16H), 2.27 (m, 8H), 2.44 (m, 8H), 4.42 (s, 8H), 5.95 (d, 8H,  $J = 7.86$  Hz), 7.63 (d, 8H,  $J = 7.91$  Hz), 7.89 (d, 4H,  $J = 7.54$  Hz), 8.21 (t, 2H,  $J = 7.80$  Hz) ppm. <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>): *δ* 20.22, 20.48, 21.09, 21.34, 21.80, 22.46, 50.32, 117.96, 120.46, 123.56, 129.48, 130.32, 137.60, 139.05, 145.08, 149.00, 153.18, 166.94 ppm. MS  $m/z$  (%) 1512 (21, M - CO<sub>2</sub>), 1421  $(96, M - PF_6)$ , 1276 (60, M - 2PF<sub>6</sub>), 1231 (34, M - 2PF<sub>6</sub> - CO<sub>2</sub>), 1141 (100,  $M - 2PF_6 - 3CO_2$ ). Anal. Calcd for  $C_{70}H_{66}N_{10}O_8P_2F_{12}Ru$ : C, 53.68; H, 4.25; N, 8.94. Found: C, 56.53; H, 4.66; N, 8.25.

[ $Ru(H<sub>2</sub>15)<sub>2</sub>$ ]( $PF<sub>6</sub>$ )<sub>2</sub>.  $Ru(10)<sub>2</sub>(PF<sub>6</sub>)<sub>2</sub>$  (0.073 g, 0.053 mmol), LiCl (0.045) g, 1.06 mmol), DBU (0.045 g, 1.06 mmol) and  $H_2O$  (0.1 g) were used in THF (25 mL) at reflux for 3 days, according to method C. The THF

Ru'6H2O: C, 40.33; H, 4.56; N, 10.22. Found: C, 40.24; H, 4.52; N, 9.91.

**Acknowledgment.** The authors are indebted to Mr. Robert Dash for initial work with  $[Ru(H<sub>2</sub>2)<sub>2</sub>]^{2+}$ , to Ms. Sundeep Shahi for the experiments with  $MV(PF_6)_2$ , to Mr. Mehrdad Ebadi and Prof. A. B. P. Lever for CV runs and discussions, and to the Natural Sciences and Engineering Research Council for funding. IC980817H